. Author manuscript; available in PMC: 2013 Apr 15.

Published in final edited form as: Biochem Pharmacol. 2011 Dec 26;83(8):1049–1062. doi: 10.1016/j.bcp.2011.12.026

Table 3.

Greater drug resistance in tumor panels and cell lines expressing wild-type p53.

A. Studies in tumor panels
Tumor panel [Ref.]	Panel size (N)	Treatment (unit of IC₅₀)	Mean IC₅₀ (N)		Fold^a
Tumor panel [Ref.]	Panel size (N)	Treatment (unit of IC₅₀)	wt p53	mu/null p53	Fold^a
HNSCC [205]	23	Cisplatin (μM)	13.7 (10)	6.8 (13)	2
Ovarian [40]	9	Cisplatin (μM)	5.7 (5)	2.0 (4)	2.9
Ovarian [206]	15	Paclitaxel (μM)	0.077 (6)	0.015 (9)	5
RCC [207]	8	Paclitaxel (μM)	1.54 (6)	0.02 (2)	77

B. Studies modulating wild-type p53 in cell lines by molecular approaches
Tumor type [Ref.]	Cell line	Treatment (unit of IC₅₀)	Mean IC₅₀		Fold^a
Tumor type [Ref.]	Cell line	Treatment (unit of IC₅₀)	wt p53	dn/ko/kd p53	Fold^a
Glioma [208]	U87MG	Carmustine (μg/mL)	7	3	2.3
Colon [209]	HCT-116	Trabectedin (nM)	14.6	4.4	3.3
Colon [210]	HCT-116	Cisplatin (μM)	3.9	0.9	4.3
Breast [209]	MCF-7	Trabectedin (nM)	>100	0.23	>400
Breast [211]	MCF-7	Cisplatin (μM)	3.38	1.69	2

Abbreviations: dn, dominant-negative; HNSCC, head and neck squamous cell carcinoma; IC₅₀, drug concentration (in μg/ml, nM, or μM) that inhibits cell proliferation by 50%; kd, knockdown; ko, knockout; N, number of cell lines in group; RCC, renal cell carcinoma; wt, wild-type.

Fold, ratio of IC₅₀ between wt p53 and mu/null p53 or dn/ko/kd p53 groups.